DK2185164T3 - Sammensætning og terapeutisk antitumorvaccine - Google Patents
Sammensætning og terapeutisk antitumorvaccineInfo
- Publication number
- DK2185164T3 DK2185164T3 DK08787072.1T DK08787072T DK2185164T3 DK 2185164 T3 DK2185164 T3 DK 2185164T3 DK 08787072 T DK08787072 T DK 08787072T DK 2185164 T3 DK2185164 T3 DK 2185164T3
- Authority
- DK
- Denmark
- Prior art keywords
- antitumorvaccine
- therapeutic
- composition
- therapeutic antitumorvaccine
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/18—Erythrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001122—Ephrin Receptors [Eph]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
- A61K39/001139—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/001149—Cell cycle regulated proteins, e.g. cyclin, CDC, CDK or INK-CCR
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
- A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
- A61K39/001153—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001158—Proteinases
- A61K39/001159—Matrix metalloproteinases [MMP]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001162—Kinases, e.g. Raf or Src
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001164—GTPases, e.g. Ras or Rho
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/00117—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001188—NY-ESO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001189—PRAME
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001191—Melan-A/MART
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001192—Glycoprotein 100 [Gp100]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001196—Fusion proteins originating from gene translocation in cancer cells
- A61K39/001197—Breakpoint cluster region-abelson tyrosine kinase [BCR-ABL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6056—Antibodies
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0705767A FR2919804B1 (fr) | 2007-08-08 | 2007-08-08 | Composition et vaccin therapeutique anti-tumoral |
US95491707P | 2007-08-09 | 2007-08-09 | |
PCT/EP2008/060492 WO2009019317A1 (en) | 2007-08-08 | 2008-08-08 | Composition and therapeutic anti-tumour vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2185164T3 true DK2185164T3 (da) | 2017-11-13 |
Family
ID=38982501
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK08787072.1T DK2185164T3 (da) | 2007-08-08 | 2008-08-08 | Sammensætning og terapeutisk antitumorvaccine |
Country Status (18)
Country | Link |
---|---|
US (4) | US9364504B2 (da) |
EP (1) | EP2185164B1 (da) |
JP (2) | JP6077195B2 (da) |
KR (1) | KR101666041B1 (da) |
CN (1) | CN101873862B (da) |
AU (1) | AU2008285595B2 (da) |
CA (1) | CA2695478C (da) |
DK (1) | DK2185164T3 (da) |
ES (1) | ES2649761T3 (da) |
FR (1) | FR2919804B1 (da) |
HK (1) | HK1148688A1 (da) |
HR (1) | HRP20171566T1 (da) |
HU (1) | HUE035983T2 (da) |
IL (1) | IL203714A (da) |
NO (1) | NO2185164T3 (da) |
PL (1) | PL2185164T3 (da) |
PT (1) | PT2185164T (da) |
WO (1) | WO2009019317A1 (da) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2919804B1 (fr) | 2007-08-08 | 2010-08-27 | Erytech Pharma | Composition et vaccin therapeutique anti-tumoral |
WO2010087335A1 (ja) * | 2009-01-27 | 2010-08-05 | 学校法人産業医科大学 | T細胞抗原受容体遺伝子、受容体α鎖及びβ鎖発現用ベクター並びに細胞障害性T細胞 |
JP5731488B2 (ja) * | 2009-05-29 | 2015-06-10 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 癌のマーカーとしてのセセルニン‐1 |
US20120207745A1 (en) * | 2009-10-27 | 2012-08-16 | Yann Godfrin | Composition to Induce Specific Immune Tolerance |
CN107058231A (zh) * | 2010-02-11 | 2017-08-18 | 中国人民解放军第二军医大学 | 携带融合蛋白基因的重组腺病毒及其制备方法和应用 |
CN108117586A (zh) | 2010-08-10 | 2018-06-05 | 洛桑聚合联合学院 | 红细胞结合性治疗剂 |
US9517257B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
US9850296B2 (en) | 2010-08-10 | 2017-12-26 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
WO2012059112A1 (en) * | 2010-11-01 | 2012-05-10 | Mahmoud Abdel Wahed Rafea | Development of medical products based on a new discovered function of red blood cells |
CN103635803A (zh) * | 2011-05-31 | 2014-03-12 | 比奥根艾迪克Ma公司 | 评估进行性多灶性白质脑病风险的方法 |
CN102973950B (zh) * | 2011-09-06 | 2015-05-27 | 四川百利药业有限责任公司 | Prame、wt1双价肿瘤dna疫苗 |
CN103958679A (zh) * | 2011-09-09 | 2014-07-30 | 转基因股份有限公司 | 变异型α-辅肌动蛋白-4的抗体 |
RS59898B1 (sr) | 2011-10-17 | 2020-03-31 | Massachusetts Inst Technology | Intraćelijsko davanje |
US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
AU2014306423B2 (en) | 2013-08-16 | 2019-04-18 | Massachusetts Institute Of Technology | Selective delivery of material to cells |
CN104415335A (zh) * | 2013-09-02 | 2015-03-18 | 北京中康万达医药科技有限公司 | 体内个体化***免疫治疗方法和装置 |
AU2014348683B2 (en) | 2013-11-18 | 2020-11-05 | Rubius Therapeutics, Inc. | Synthetic membrane-receiver complexes |
FR3017299B1 (fr) | 2014-02-12 | 2018-05-18 | Erytech Pharma | Composition pharmaceutique comprenant des erythrocytes encapsulant une enzyme a plp et son cofacteur |
US10953101B2 (en) | 2014-02-21 | 2021-03-23 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
US10946079B2 (en) | 2014-02-21 | 2021-03-16 | Ecole Polytechnique Federale De Lausanne | Glycotargeting therapeutics |
JP6744227B2 (ja) | 2014-02-21 | 2020-08-19 | エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ(ウペエフエル)Ecole Polytechnique Federale de Lausanne (EPFL) | 糖標的化治療剤 |
US10046056B2 (en) | 2014-02-21 | 2018-08-14 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
RU2736495C2 (ru) | 2014-04-01 | 2020-11-17 | Рубиус Терапьютикс, Инк. | Способ и композиции для иммуномодуляции |
US10077453B2 (en) | 2014-07-30 | 2018-09-18 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
CN107109362A (zh) | 2014-10-31 | 2017-08-29 | 麻省理工学院 | 递送生物分子至免疫细胞 |
US10526573B2 (en) | 2014-11-14 | 2020-01-07 | Massachusetts Institute Of Technology | Disruption and field enabled delivery of compounds and compositions into cells |
JP7278027B2 (ja) | 2015-01-12 | 2023-05-19 | マサチューセッツ インスティテュート オブ テクノロジー | マイクロ流体送達による遺伝子編集 |
EP3320082B1 (en) | 2015-07-09 | 2023-05-24 | Massachusetts Institute of Technology | Delivery of materials to anucleate cells |
US11613759B2 (en) | 2015-09-04 | 2023-03-28 | Sqz Biotechnologies Company | Intracellular delivery of biomolecules to cells comprising a cell wall |
US20180256541A1 (en) * | 2015-09-18 | 2018-09-13 | The General Hospital Corporation Dba Massachusetts General Hospital | Compositions having anti-fugetactic properties for treatment of cancer |
KR102632490B1 (ko) | 2015-10-07 | 2024-02-02 | 생귀 바이오 피티와이. 엘티디 | 혈액 제제 및 프로파일링 |
EP3393482A4 (en) * | 2015-12-22 | 2019-08-21 | Sangui Bio Pty. Ltd | THERAPEUTIC PROCEDURES USING ERYTHROCYTES |
LT3402491T (lt) | 2016-01-11 | 2022-02-25 | Rubius Therapeutics, Inc. | Kompozicijos ir būdai, susiję su daugiamodalinėmis terapinėmis ląstelių sistemomis, skirti vėžio indikacijoms |
CN105646676A (zh) * | 2016-03-17 | 2016-06-08 | 南通大学 | 小分子多肽Prdx5截短体及其载体和应用 |
AU2017308889B2 (en) | 2016-08-09 | 2023-11-09 | President And Fellows Of Harvard College | Programmable Cas9-recombinase fusion proteins and uses thereof |
JP6314201B1 (ja) * | 2016-11-21 | 2018-04-18 | テラファーマ株式会社 | 樹状細胞洗浄液及びこれを用いた樹状細胞の洗浄方法、並びに樹状細胞含有組成物の調製方法 |
US11693006B2 (en) | 2016-12-20 | 2023-07-04 | Sangui Bio Pty. Ltd | Blood profiling with protease inhibitors |
WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
WO2018165504A1 (en) | 2017-03-09 | 2018-09-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
WO2018165631A1 (en) * | 2017-03-09 | 2018-09-13 | President And Fellows Of Harvard College | Cancer vaccine |
WO2018232176A1 (en) | 2017-06-16 | 2018-12-20 | The University Of Chicago | Compositions and methods for inducing immune tolerance |
JP2020534795A (ja) | 2017-07-28 | 2020-12-03 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ファージによって支援される連続的進化(pace)を用いて塩基編集因子を進化させるための方法および組成物 |
WO2019032628A1 (en) | 2017-08-07 | 2019-02-14 | The Regents Of The University Of California | GENERATING PLATFORM FOR SAFE CELLULAR THERAPEUTIC AGENTS |
US10960071B2 (en) | 2017-08-07 | 2021-03-30 | The Regents Of The University Of California | Platform for generating safe cell therapeutics |
WO2019139645A2 (en) | 2017-08-30 | 2019-07-18 | President And Fellows Of Harvard College | High efficiency base editors comprising gam |
US11795443B2 (en) | 2017-10-16 | 2023-10-24 | The Broad Institute, Inc. | Uses of adenosine base editors |
CN110078811B (zh) * | 2018-01-25 | 2022-02-11 | 中国医学科学院医药生物技术研究所 | 一种具有抗肿瘤活性的多肽imb-p1及其应用 |
JP6385607B2 (ja) * | 2018-02-13 | 2018-09-05 | テラファーマ株式会社 | 樹状細胞ワクチン |
SG11202008261WA (en) * | 2018-03-08 | 2020-09-29 | Rubius Therapeutics Inc | Therapeutic cell systems and methods for treating cancer and infectious diseases |
AU2020228648A1 (en) | 2019-02-28 | 2021-10-14 | Sqz Biotechnologies Company | Delivery of biomolecules to PBMCs to modify an immune response |
JP2022526908A (ja) | 2019-03-19 | 2022-05-27 | ザ ブロード インスティテュート,インコーポレーテッド | 編集ヌクレオチド配列を編集するための方法および組成物 |
US11679388B2 (en) | 2019-04-08 | 2023-06-20 | Sqz Biotechnologies Company | Cartridge for use in a system for delivery of a payload into a cell |
TWI776276B (zh) * | 2019-11-13 | 2022-09-01 | 中國醫藥大學 | 異種組織細胞組合物治療癌症之用途 |
JPWO2021132636A1 (da) * | 2019-12-27 | 2021-07-01 | ||
AU2021267940A1 (en) | 2020-05-08 | 2022-12-08 | President And Fellows Of Harvard College | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
AU2021270347A1 (en) | 2020-05-11 | 2022-12-15 | Erytech Pharma | Red cell extracellular vesicles (RCEVs) containing cargoes and methods of use and production thereof |
CN113350499B (zh) * | 2021-06-29 | 2022-06-14 | 贵州医科大学 | 鸡卵清蛋白OVA mRNA在制备非特异性免疫刺激剂中的应用 |
CN114432261B (zh) * | 2022-02-24 | 2023-11-28 | 初源汇企业管理(深圳)合伙企业(有限合伙) | 一种靶向递送疫苗的制备方法及红细胞疫苗 |
CN117965442A (zh) * | 2022-10-26 | 2024-05-03 | 北京睿脉医药科技有限公司 | 一种将治疗性分子偶联至成熟红细胞表面的方法及应用 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1051382A (da) | 1900-01-01 | |||
DE2740053A1 (de) | 1977-09-06 | 1979-05-03 | Klaus Prof Dr Med Gersonde | Verwendung von allosterischen effektoren mit hilfe von lipidvesikeln ueber eine irreversible inkorporierung zwecks verbesserter o tief 2 -entladung des haemoglobins in erythrozyten |
US4327710A (en) | 1980-06-18 | 1982-05-04 | The United States Of America As Represented By The Secretary Of Agriculture | Process for encapsulating additives in resealed erythrocytes for disseminating chemicals via the circulatory system |
FR2529463B1 (fr) | 1982-07-05 | 1986-01-10 | Centre Nat Rech Scient | Procede et dispositif pour l'encapsulation dans les erythrocytes d'au moins une substance a activite biologique, notamment des effecteurs allosteriques de l'hemoglobine et erythrocytes ainsi obtenus |
US4478824A (en) | 1983-08-08 | 1984-10-23 | Franco Robert S | Method for altering red blood cell function and survival |
JPH0235081A (ja) | 1988-07-26 | 1990-02-05 | Agency Of Ind Science & Technol | アルギニン・デイミナーゼおよびその用途 |
JPH0253490A (ja) | 1988-08-16 | 1990-02-22 | Agency Of Ind Science & Technol | アルギニン・デイミナーゼ遺伝子 |
EP0361150B1 (de) | 1988-09-30 | 1994-12-14 | Siemens Aktiengesellschaft | Verfahren zum synchronisierten Umtasten eines Polarisationszustandes eines optischen Sendesignals eines optischen Übertragungssystems mit Überlagerungsempfang und Vorrichtung zur Durchführung des Verfahrens |
JP2900279B2 (ja) | 1989-08-02 | 1999-06-02 | 株式会社ジャパンエナジー | 新規なアルギニンデイミナーゼ、その製造法及び該酵素を有効成分とする制癌剤 |
FR2678512B1 (fr) | 1991-07-03 | 1995-06-30 | Novacell | Machine a internaliser. |
JP3004788B2 (ja) | 1991-10-28 | 2000-01-31 | 株式会社ジャパンエナジー | アルギニンデイミナーゼ発現ベクター、形質転換微生物およびアルギニンデイミナーゼの製造法 |
US5372942A (en) | 1992-02-10 | 1994-12-13 | Coriell Institute For Medical Research | Protease K resistant arginine deiminase, its method of preparation and its use as an anti-neoplastic agent |
EP0690671B1 (en) | 1993-03-23 | 2004-08-04 | Cbr Laboratories, Inc. | Method and apparatus for encapsulation of biologically-active substances in cells |
US6218166B1 (en) * | 1994-12-09 | 2001-04-17 | John Wayne Cancer Institute | Adjuvant incorporation into antigen carrying cells: compositions and methods |
US5804183A (en) | 1997-01-31 | 1998-09-08 | Enzon, Inc. | Arginine deminase derived from mycoplasma arthritidis and polymer conjugates containing the same |
AU6542898A (en) * | 1997-03-05 | 1998-09-22 | John Wayne Cancer Institute | Sialyl lewis antigens as targets for immunotherapy |
EP0882448B1 (en) * | 1997-05-05 | 2005-01-12 | DIDECO S.r.l. | Method of encapsulating biologically active agents within erythrocytes and apparatus therefor |
US6183738B1 (en) | 1997-05-12 | 2001-02-06 | Phoenix Pharamacologics, Inc. | Modified arginine deiminase |
DE60026313D1 (de) | 1999-07-23 | 2006-04-27 | Uutech Ltd | Sensibilisierung von roten blutkörperchen gegenüber ultraschall durch einwirkung eines elektrischen feldes |
WO2002009741A1 (en) | 2000-07-27 | 2002-02-07 | Angiolab, Inc. | The pharmaceutical composition comprising arginine deiminase for inhibiting angiogenesis |
WO2002010177A1 (en) | 2000-08-01 | 2002-02-07 | Gmp Companies, Inc. | Ammonium salts of inositol hexaphosphate and uses thereof |
US7037500B1 (en) * | 2000-09-08 | 2006-05-02 | The Trustees Of Columbia University In The City Of New York | Method for using phagocytic particles and ATP receptors to deliver antigens to MHC class I receptors to induce immunity against microbial pathogens or tumors or to suppress immunity |
DE10335833A1 (de) * | 2003-08-05 | 2005-03-03 | Curevac Gmbh | Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie |
FR2873925B1 (fr) | 2004-08-05 | 2006-10-13 | Erytech Pharma Soc Par Actions | Procede et dispositif de lyse-rescellement pour l'incorporation de principe actif notamment asparaginase ou inositol hexaphosphate, dans des erythrocytes |
FR2884717B1 (fr) | 2005-04-25 | 2009-07-03 | Erytech Pharma Soc Par Actions | Erythrocytes renfermant de l'arginine deiminase |
FR2919804B1 (fr) | 2007-08-08 | 2010-08-27 | Erytech Pharma | Composition et vaccin therapeutique anti-tumoral |
US20120207745A1 (en) | 2009-10-27 | 2012-08-16 | Yann Godfrin | Composition to Induce Specific Immune Tolerance |
US8530011B2 (en) | 2010-12-13 | 2013-09-10 | Southwall Technologies Inc. | Insulating glass unit with crack-resistant low-emissivity suspended film |
-
2007
- 2007-08-08 FR FR0705767A patent/FR2919804B1/fr active Active
-
2008
- 2008-08-08 WO PCT/EP2008/060492 patent/WO2009019317A1/en active Application Filing
- 2008-08-08 US US12/672,094 patent/US9364504B2/en active Active
- 2008-08-08 JP JP2010519476A patent/JP6077195B2/ja active Active
- 2008-08-08 KR KR1020107004794A patent/KR101666041B1/ko active IP Right Grant
- 2008-08-08 DK DK08787072.1T patent/DK2185164T3/da active
- 2008-08-08 AU AU2008285595A patent/AU2008285595B2/en active Active
- 2008-08-08 ES ES08787072.1T patent/ES2649761T3/es active Active
- 2008-08-08 CA CA2695478A patent/CA2695478C/en active Active
- 2008-08-08 PT PT87870721T patent/PT2185164T/pt unknown
- 2008-08-08 HU HUE08787072A patent/HUE035983T2/hu unknown
- 2008-08-08 NO NO08787072A patent/NO2185164T3/no unknown
- 2008-08-08 CN CN200880110270.0A patent/CN101873862B/zh active Active
- 2008-08-08 EP EP08787072.1A patent/EP2185164B1/en active Active
- 2008-08-08 PL PL08787072T patent/PL2185164T3/pl unknown
-
2010
- 2010-02-04 IL IL203714A patent/IL203714A/en active IP Right Grant
-
2011
- 2011-03-23 HK HK11102915.5A patent/HK1148688A1/xx unknown
-
2016
- 2016-05-13 US US15/154,273 patent/US9950049B2/en active Active
- 2016-09-01 JP JP2016170936A patent/JP6352996B2/ja active Active
-
2017
- 2017-10-16 HR HRP20171566TT patent/HRP20171566T1/hr unknown
-
2018
- 2018-04-24 US US15/961,226 patent/US10780151B2/en active Active
-
2020
- 2020-08-21 US US17/000,007 patent/US20210077602A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20210077602A1 (en) | 2021-03-18 |
US10780151B2 (en) | 2020-09-22 |
JP2016196517A (ja) | 2016-11-24 |
FR2919804A1 (fr) | 2009-02-13 |
JP6352996B2 (ja) | 2018-07-04 |
IL203714A (en) | 2014-05-28 |
ES2649761T3 (es) | 2018-01-15 |
US20120009140A1 (en) | 2012-01-12 |
CA2695478A1 (en) | 2009-02-12 |
NO2185164T3 (da) | 2018-01-27 |
FR2919804B1 (fr) | 2010-08-27 |
US9950049B2 (en) | 2018-04-24 |
CA2695478C (en) | 2018-05-08 |
AU2008285595B2 (en) | 2012-08-09 |
PL2185164T3 (pl) | 2018-01-31 |
EP2185164B1 (en) | 2017-08-30 |
KR20100075832A (ko) | 2010-07-05 |
PT2185164T (pt) | 2017-11-28 |
KR101666041B1 (ko) | 2016-10-13 |
HUE035983T2 (hu) | 2018-06-28 |
EP2185164A1 (en) | 2010-05-19 |
CN101873862B (zh) | 2014-10-01 |
US20160324946A1 (en) | 2016-11-10 |
HRP20171566T1 (hr) | 2017-11-17 |
WO2009019317A1 (en) | 2009-02-12 |
US20180344822A1 (en) | 2018-12-06 |
AU2008285595A1 (en) | 2009-02-12 |
CN101873862A (zh) | 2010-10-27 |
JP2010535744A (ja) | 2010-11-25 |
HK1148688A1 (en) | 2011-09-16 |
US9364504B2 (en) | 2016-06-14 |
JP6077195B2 (ja) | 2017-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2185164T3 (da) | Sammensætning og terapeutisk antitumorvaccine | |
DK2170827T3 (da) | Indolin-2-oner og aza-indolin-2-oner | |
DK2222675T3 (da) | 5-anilinoimidazopyridiner og fremgangsmåder til deres anvendelse | |
BRPI0812562A2 (pt) | composições terapêuticas anti-cd20 e métodos | |
DK2220320T3 (da) | Forseglet enhed og mellemstykke | |
DK3092901T3 (da) | Quinolonanaloger og fremgangsmåder relateret dertil | |
DK3345625T3 (da) | Farmaceutisk sammensætning og indgivelser deraf | |
DK2185552T3 (da) | Dipeptoid-prodrugs og anvendelse heraf | |
DK3338790T3 (da) | Oligopeptid-forbindelser og anvendelser deraf | |
DK2118140T3 (da) | Humancytomegalovirus-neutraliserende antistoffer og anvendelse deraf | |
DK2001556T3 (da) | Thioninium-forbindelser og anvendelse deraf | |
DK2107905T3 (da) | Fast sammensætning omfattende alogliptin og pioglitazon | |
DK2152078T3 (da) | Formuleringer indeholdende clopidogrel og sulfoalkylethercyclodextrin og anvendelsesfremgangsmåder | |
DK2193097T3 (da) | Nanostrukturforstærkede kompositartikler og fremgangsmåder | |
BRPI0813647A2 (pt) | Piperazinil oxoalquil tetrahidro-beta-carbolinas e análogos relacionados | |
DE602007010795D1 (de) | Blattsauger und -häcksler | |
DK3263589T5 (da) | Peptidsekvenser og sammensætninger | |
DK2079485T3 (da) | Phenylpropionamidforbindelser og anvendelsen deraf | |
DK2035369T3 (da) | Terapeutiske | |
DK2144905T3 (da) | Terapeutiske midler | |
ATE526567T1 (de) | Zusammensteller und zusammenstellungsverfahren | |
DK2160336T3 (da) | Forbindelsesmekanisme og fremgangsmåde | |
DK2154966T3 (da) | Benzimidazoler og farmaceutiske sammensætninger deraf | |
DK2313404T3 (da) | Quinuclidin-carbonat-derivater og medicinsk sammensætning deraf | |
BRPI0816789A2 (pt) | Goji e inflamação |